Oxurion H1 net loss narrows 24% to EUR 904,000

• Oxurion posted a loss for the period of EUR 904,000 for the six months ended June 30, 2026, narrowing 24%.
• Basic earnings per share improved to a loss of EUR 0.01 from a loss of EUR 0.24.
• Sales were EUR 591,000 versus no sales a year earlier, related to clinical data management and eCRF solutions at Axiodis CRO.
• Operating result improved 58% to a loss of EUR 755,000.
• Cash and cash equivalents fell to EUR 31,000 at June 30, 2026, from EUR 430,000 at end-2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oxurion NV published the original content used to generate this news brief on September 30, 2026, and is solely responsible for the information contained therein.